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In pemphigus vulgaris the major pathogenic anti-
body binds desmoglein-3, and mediates mucosal
disease. Development of cutaneous disease is associ-
ated with acquisition of antibodies to desmoglein-1.
In pemphigus foliaceus, and its endemic form, fogo
selvagem by contrast, the major pathogenic antibody
recognizes desmoglein-1 and mediates cutaneous
disease only. In this study, we sought to determine
the prevalence of antibodies to desmoglein-3 in
patients with pemphigus foliaceus and fogo selva-
gem. We produced recombinant desmoglein-1 and
desmoglein-3, and used them in highly sensitive and
speci®c enzyme-linked immunosorbent assays, as
well as immunoprecipitation assays. We detected
antibodies to desmoglein-3 in 19 of 276 patients with
pemphigus foliaceus and fogo selvagem, who had
cutaneous disease only. We showed that these anti-
bodies to desmoglein-3 could be absorbed in a con-
centration-dependent manner by desmoglein-3 but
not by desmoglein-1. Also antibodies to desmoglein-1
could be absorbed in a concentration-dependent
manner by desmoglein-1 but not desmoglein-3. This
suggests that two separate species of antibody are
present rather than one antibody capable of cross-
reacting with both desmoglein-1 and desmoglein-3.
Finally, it was shown that af®nity-puri®ed antibodies
to desmoglein-3 from patients with pemphigus
foliaceus and fogo selvagem induced a pemphigus
vulgaris-like skin disease in mice by passive transfer.
These results suggest that a subset of patients with
pemphigus foliaceus and fogo selvagem have anti-
bodies to desmoglein-3 that may be involved in the
pathogenesis of their cutaneous disease. Key words:
autoantibodies/autoimmunity/desmoglein/fogo selvagem/
pemphigus. J Invest Dermatol 118:806±811, 2002
P
emphigus vulgaris (PV) is characterized by the gradual
onset of blisters and erosions involving not only the
skin but also mucous membranes (Lever, 1965).
Approximately one-third of PV patients may have
mucosal lesions months before the diagnosis of PV is
established. The vesicles are intraepidermal and located above the
epidermal basal cell layer (suprabasal blisters). In contrast,
pemphigus foliaceus (PF) and fogo selvagem (FS) are characterized
by cutaneous blisters and erosions only, without mucosal involve-
ment (Lever, 1965; Diaz et al, 1989). The vesicles in PF and FS are
located just below the stratum corneum. Blister formation in PV,
PF, and FS results from a progressive epidermal cell detachment
also known as acantholysis. Electron microscopic examination of
lesional epidermis in these patients shows separation of desmosomes
with widening of the epidermal intercellular spaces (ICS).
Keratinocytes round up and exhibit retraction of intermediate
®laments around the nucleus (Lever, 1965). Patients with PV, PF,
and FS produce anti-epidermal autoantibodies, which can be
detected in the ICS of perilesional epidermis and circulating in the
patients' serum using immuno¯uorescence (IF) techniques
(Beutner and Jordon, 1964; Beutner et al, 1968; Diaz et al, 1989).
The serum titers of autoantibodies by indirect IF roughly correlate
with disease activity and extent of the skin involvement. The IgG
fractions of PV (Anhalt et al, 1982) and PF (Roscoe et al, 1985) sera
are pathogenic in passive transfer experiments using neonatal mice.
The injected animals display the key clinical, histologic, and
immunologic features of each disease.
The epidermal autoantigens recognized by antibodies and T cells
in PF/FS and PV have been identi®ed as desmoglein-1 (dsg1) and
desmoglein-3 (dsg3), respectively (Stanley et al, 1984; Labib et al,
1990; Amagai et al, 1991; Olague-Alcala et al, 1994; Emery et al,
1995; Wucherpfennig et al, 1995; Lin et al, 1997a, b, 2000). Dsg1
and dsg3 are transmembrane desmosomal glycoproteins that belong
to the cadherin family of proteins (Buxton et al, 1993). These
molecules exhibit extensive amino acid homology, especially in
their extracellular domains (Fig 1). Recombinant dsg1 and dsg3,
generated in the baculovirus expression system, are capable of
absorbing pathogenic antibodies from the sera of PF or PV patients
(Amagai et al, 1994, 1995)
It appears that genetic predisposition is a common feature in
patients developing PV or PF, as each disease exhibits unique DR
alleles. FS shows a strong association with the HLA-DRB1*0102,
0404, 1402, 1602 alleles (Cerna et al, 1993; Moraes et al, 1997),
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whereas PV is linked to the HLA-DRB1*0402 and 1401 alleles
(Scharf et al, 1988; Sinha et al, 1988; Szafer et al, 1988; Ahmed et al,
1990, 1991).
Recent reports have documented the existence of two clinical
and serologic variants of PV (Ding et al, 1997; Amagai et al, 1999;
Miyagawa et al, 1999; Harman et al, 2000a, b). A mucosal variant
exhibits a predominantly anti-dsg3 antibody response and a
mucocutaneous form, comprising approximately 50% of the
patients, is characterized by a mixed anti-dsg3 and anti-dsg1
antibody response and a T cell response to these antigens (Lin et al,
1997b). It has been demonstrated that both af®nity-puri®ed anti-
dsg3 and anti-dsg1 autoantibodies from these PV sera are patho-
genic in the mouse model (Ding et al, 1999). In these studies, each
antibody system was shown to reproduce the phenotype of each
disease, i.e., antibodies to dsg3 induced PV-like lesions and
antibodies to dsg1 induced PF-like lesions. There was no
immunologic cross-reactivity between these autoantibody systems.
Interestingly, it has been reported recently that patients with classic
clinical, histologic, and immunologic ®ndings of PV may evolve
into PF (Iwatsuki et al, 1991; Kawana et al, 1994; Chorzelski et al,
1995; Chang et al, 1997). The evolution of PV into PF is associated
with a serologic switch from antibodies against dsg3, typical of PV,
to antibodies against dsg1, which are a marker of PF.
The transition from PF into PV has also been described,
however, this progression appears to be extremely rare (Ishii et al,
2000). It is well established that the sera of the majority of PF and
FS possess a predominantly anti-dsg1 IgG response (Stanley et al,
1986; Warren et al, 2000). The frequency of anti-dsg3 auto-
antibodies in PF and FS patients, however, is unknown.
In this communication, using speci®c enzyme linked immuno-
sorbent assays (ELISA) methods, we found anti-dsg3 autoantibodies
in 19 of 276 patients with PF and FS. The reactivity of these
autoantibodies with dsg3 was further con®rmed by immuno-
precipitation using puri®ed recombinant desmoglein-3 (rdsg3). The
speci®c binding of anti-dsg3 autoantibodies detected by ELISA was
inhibited in a concentration-dependent manner by puri®ed rdsg3,
but not by puri®ed rdsg1. Under the same experimental conditions,
antibodies to dsg1 were inhibited by rdsg1 but not by rdsg3.
Furthermore, using the passive transfer mouse model, we found
that puri®ed anti-dsg3 antibodies from PF and FS patients are
capable of inducing PV-like lesions in neonatal mice. These results
suggest that a subset of patients with PF and FS have antibodies to
dsg3 that may be involved in the pathogenesis of their disease.
MATERIALS AND METHODS
Source of sera We tested sera from 35 PF patients (25 from the U.S.A.
and 10 from Japan) and 241 FS patients from Brazil (40 from Campo
Grande, ®ve from Sao Paulo, 44 from Belho Horizonte, 62 from Goiania,
57 from Brazilia, and 33 from Limao Verde). The diagnosis of PF and FS
was established clinically, histologically, and immunologically, as reported
previously (Diaz et al, 1989). These patients had active disease and none
had mucosal lesions. We also tested sera from patients with other
cutaneous diseases such as bullous pemphigoid (n = 20), lupus
erythematosus (n = 19), herpes gestationis (n = 23), and PV (n = 83).
Patients with PV included 53 from the U.S.A., seven from Spain, 13 from
Brazil, and 10 from Japan. We also tested normal donors from the U.S.A.
(n = 50) as controls. No pooled sera were used in this study.
Production and puri®cation of rdsg1 and rdsg3 The expression of
the extracellular domain of dsg3 using the baculovirus system has been
described previously (Ding et al, 1999). In order to facilitate the
puri®cation of this protein, a six histidine stretch was engineered
immediately downstream of the dsg3 extracellular domain. The rdsg3
was puri®ed using a Ni+ NTA column following procedures suggested
by the manufacturer (Qiagen, Valencia, CA). The extracellular domain
of dsg1 (rsdg1) was produced by similar methods (Ding et al, 1999). The
purity of each recombinant protein was assured by sodium dodecyl
sulfate±polyacrylamide gel electrophoresis and immunoblot analysis.
Establishment of dsg1 and dsg3 ELISA The rdsg1and rdsg3 ELISA
were established following procedures described by Warren et al (2000)
except that mouse monoclonal anti-human IgG conjugated to
horseradish-peroxidase (Zymed Laboratories, San Francisco, CA) was
used as a secondary antibody. Each ELISA plate contained three dilutions
of a standard positive serum sample that were used to correct for plate-
to-plate variability by linear regression analysis. Logarithmic trans-
formation was used to analyze the assay results. The cut-off values were
set at the mean plus 3 SD of values of the normal subjects from the
U.S.A. This resulted in a cut-off for the dsg1 ELISA of 0.3 OD units
and for the dsg3 ELISA of 0.48 OD units
Figure 1. Molecular structure of the extra-
cellular region of dsg1 and dsg3. dsg1 and
dsg3 exhibit ®ve major cadherin-like domains
(EC-1, EC-2, EC-3, EC-4, and EC-5), stretching
from the N-terminus (EC-1) to the C-terminus
(transmembrane domain). The six-histidine tag is
attached to the C-terminus. The black strips
represent Ca2+ binding motifs. The recombinant
ectodomains of rdsg1 and rdsg3 are expressed in
the baculovirus system as a soluble glycopeptide of
approximately 66 kDa.
Figure 2. Sera from PV patients speci®cally react with rdsg3
using the dsg3 ELISA. The cut-off value for this assay was set at the
mean of 50 normal human sera plus 3 SD, equal to 0.48 OD units. All
50 normal sera were negative, as were 20 patients with bullous
pemphigoid (BP), 19 with systemic lupus erythematosus (SLE), and 23
with herpes gestationis (HG). Eighty-two of 83 patients with PV were
positive. The one PV patient that was negative was also in clinical
remission.
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The inhibition of the ELISA assays was performed by incubating a
®xed dilution of PF or FS serum in Tris-buffered-saline (TBS), with
calcium 5 mM, pH 7.3 (TBS Ca2+), with different amounts of rdsg3 or
rdsg1 (0±8 mg) at room temperature for 1 h. Following a centrifugation
step at 10,000 3 g at 4°C for 10 min, the supernatant was tested by
rdsg3 ELISA (or rdsg1 ELISA).
Immunoprecipitation assay The immunoprecipitation of rdsg3 was
carried out as described previously (Ding et al, 1999) with the following
modi®cations. Three micrograms of rdsg3 (or rdsg1) was ®rst incubated
with 3 ml of serum from PF and FS patients for 1 h at room
temperature. Subsequently, 30 ml of a 50% suspension of immobilized
recombinant Protein G (Zymed) was added and incubated for 90 min.
The protein G immune complexes were washed three times with TBS-
Ca2+/0.05% Tween buffer (pH 7.3) and then extracted using 30 ml of
reducing buffer (4% sodium dodecyl sulfate, 10% 2-mercaptoethanol
from Sigma) and boiled for 5 min. The extracts were then fractionated
using 7.5% sodium dodecyl sulfate±polyacrylamide gel electrophoresis
and the protein bands analyzed by western blotting using rabbit anti-dsg3
(or rabbit anti-dsg1) as the primary antibody and horseradish peroxidase-
labeled goat anti-rabbit IgG (Zymed) as the second antibody at a dilution
of 1:10,000. The speci®c rdsg3 bands (or dsg1 bands) were visualized by
enzymic chemiluminescence western blotting and autoradiography
(Amersham Pharmacia Biotech, Buckinghamshire, U.K.).
Af®nity puri®cation of anti-dsg1 and anti-dsg3 autoantibodies
from PF/FS sera The anti-dsg1 and anti-dsg3 autoantibodies from PF
and FS sera were puri®ed using rdsg1 or rdsg3 Ni-NTA columns as
previously described (Ding et al, 1999). The af®nity-puri®ed
autoantibodies were dialyzed against phosphate-buffered saline,
Table I. Anti-dsg1 and anti-dsg3 autoantibodies in a subset
of 19 patients with FS and PF
Patient code
ELISAa
Indirect IF titerdsg1b dsg3c
BH18 5.683 1.536 1:160
BH26 9.964 2.034 1:2560
BH28 9.974 1.416 1:160
BH30 8.332 2.113 1:320
BH39 9.966 2.603 1:320
Bra19 9.982 5.197 1:320
Bra48 5.900 1.300 1:640
Bra49 2.630 2.083 1:80
Bra 50 1.899 1.495 1:40
Bra52 0.435 3.831 1:320
Bra55 3.078 2.167 1:20
Bra 61 6.956 2.216 1:640
CG14 9.977 9.980 1:1280
CG44 9.859 4.788 1:160
CG50 9.715 1.370 1:160
GO101 9.972 1.330 1:1280
FS12 5.567 2.517 1:80
FS26 4.403 2.492 1:80
PH 4.462 3.246 1:640
aThe cut-off value of the ELISA was set at the mean of the 50 normal sera plus
3 SD.
bThe cut-off for the dsg1 ELISA was 0.30 OD units.
cThe cut-off for the dsg3 ELISA was 0.48 OD units.
Figure 3. All 19 patients with antibodies to dsg3 by ELISA were
also positive by immunoprecipitation. The autoradiogram shows
immunoprecipitates analyzed by sodium dodecyl sulfate±polyacrylamide
gel electrophoresis. Lane P: PV patient included as a positive dsg3
control. Lane C: Normal human serum included as a negative control.
Lanes 1±19: All 19 patients with PF or FS with antibodies to dsg3 by
ELISA.
Figure 4. Competitive inhibition of the dsg1 and dsg3 ELISA by
soluble recombinant dsg1 and dsg3. PF or FS serum was incubated
with rdsg1 or rdsg3 (0±8 mg) and then tested in the dsg1 and dsg3
ELISA. (A) Puri®ed rdsg3 was capable of absorbing anti-dsg3 activity,
but not anti-dsg1 activity. (B) Puri®ed rdsg1 was capable of absorbing
ant-dsg1 activity but not anti-dsg3 activity. The asterisk sign indicates
that the ELISA titers of samples are below the cut-offs.
Table II. Pathogenicity of af®nity puri®ed anti-dsg1 and










Anti-dsg1 (FS12 serum) 5 3 + subcorneal (+)
Anti-dsg3 (FS12 serum) 5 3 + suprabasal (+)
Anti-dsg1 (FS26 serum) 4 3 + subcorneal (+)
Anti-dsg3 (FS26 serum) 4 3 + suprabasal (+)
Anti-dsg1 (PH serum) 5 3 + subcorneal (+)
Anti-dsg3 (PH serum) 5 3 + suprabasal (+)
aAf®nity puri®ed anti-dsg1 and anti-dsg3 autoantibodies from patients with PF
and FS were passively transferred into neonatal mice. The dose of anti-dsg1 IgG
was 200 mg per g of body weight, whereas the dose of anti-dsg3 was 130 mg per g
of body weight.
bMice were examined clinically 18 h after IgG injection. Disease activity is
scored on a scale of no disease (±) to severe skin lesions (+ + +).
cDirect IF is reported as positive (+), if FITC-labeled anti-human IgG antibodies
stained the epidermal intercellular spaces.
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concentrated, and ®lter sterilized. They were then characterized by
ELISA assays. These antibodies were then used in passive transfer
experiments in neonatal mice as described below.
Induction of experimental pemphigus by passive transfer
experiments Institutional approval from UNC-Chapel Hill IRB was
obtained for the animal studies. Approximately 200 mg per g body
weight of af®nity-puri®ed anti-dsg1 or anti-dsg3 antibodies diluted in
phosphate-buffered saline was administered intradermally to neonatal
BALB/C mice following established procedures (Anhalt et al, 1982;
Roscoe et al, 1985; Ding et al, 1999). The skin of neonatal mice was
examined 18 h after the IgG injection and any signs of skin disease
recorded. The animals were then killed. Specimens were obtained from
lesional skin for histologic examination by light microscopy. Perilesional
skin samples were also obtained for direct IF analysis, which employed
monospeci®c ¯uorescein isothiocyanate-conjugated goat anti-human IgG
(Kirkeggard & Perry Laboratories, Gaithersburg, MD).
RESULTS
Sensitivity and speci®city of the dsg3 ELISA The rdsg3
ELISA was highly sensitive, and detected antibodies to dsg3 in 82 of
83 patients with PV (sensitivity: 98.8%). All 50 normal subjects
were negative, as well as all 20 patients with bullous pemphigoid, all
19 patients with lupus erythematosus and all 23 patients with herpes
gestationis, giving an overall speci®city of 100% (Fig 2).
A subset of patients with PF and FS produce antibodies to
dsg3 Employing the dsg3 ELISA described above we tested a
Figure 5. Anti-dsg1 and anti-dsg3 autoantibody fractions from patients with PF and FS are pathogenic. Neonatal BALB/C mice were
injected intradermally with af®nity puri®ed anti-dsg1 autoantibodies (A±C) or anti-dsg3 autoantibodies (D±F), respectively. The clinical, immunologic,
and histologic evaluations were performed 18 h post-IgG injection. Mice injected with anti-dsg1 autoantibodies developed blisters (A), which were
located in the subcorneal region of the epidermis (B). The anti-dsg1 autoantibodies were detected bound to the epidermal ICS by direct IF (C). Mice
injected with anti-dsg3 autoantibodies developed blisters (D), which were located in the suprabasilar region of the epidermis (E). Autoantibodies were
detected bound to the epidermal ICS by direct IF (F). The pathogenicity of the anti-dsg3 and anti-dsg1 autoantibodies fractions was blocked by
preincubation of these fractions with puri®ed rdsg3 and rdsg1, respectively (data not shown).
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large number of serum samples from PF and FS patients. These
samples were obtained from several regions of Brazil (n = 241),
Japan (n = 25), and the U.S.A. (n = 10). We detected antibodies
to dsg3 in 28% of the nonendemic PF samples (one of 35), and in
7.5% of the FS patients (18 of 241).This difference was not
statistically signi®cant. (Using Fisher's exact test and one-sided
p-value, p = 0.28. The two-sided p-value is 0.48.)
The corrected OD495 readings ranged from 1.3 to 9.98
(Table I). The sera was also assayed by immunoprecipitation
(Fig 3). Antibodies to dsg3 were detected in all 19 patients with PF
and FS by immunoprecipitation. Sera of these patients also
immunoprecipitated rdsg1 (not shown). Serum samples from
rdsg3 ELISA negative PF and FS patients, as well as sera from
bullous pemphigoid, herpes gestationis, and lupus erythematosus
failed to react with rdsg3 by immunoprecipitation (not shown).
Preincubation with rdsg3 inhibits only reactivity with dsg3,
and preincubation with rdsg1 inhibits only reactivity with
dsg1 Using serum from patients with PF and FS who had
detectable antibodies to dsg3, we added a preincubation step with
rdsg3, and then tested the sera in the ELISA assay. As shown in
Fig 4A preincubation with puri®ed rdsg3 removes antibodies to
dsg3 in a concentration-dependent manner, but has minimal effect
on antibodies to dsg1. Pre-incubation with rdsg1 (Fig 4B) removes
antibodies to dsg1 in a concentration-dependent manner but has
minimal effect on antibodies to dsg3. These data therefore provide
strong evidence that these 19 PF/FS patients exhibit two
independent antigen±antibody systems, i.e., anti-dsg3 and anti-
dsg1.
Antibodies to dsg3 and dsg1 from PF and FS patients are
pathogenic Antibodies from two patients with FS and one with
PF were af®nity puri®ed on dsg1 and dsg3 af®nity columns and the
purity of the preparations con®rmed by dsg1 and dsg3 ELISA.
Af®nity-puri®ed antibodies were passively transferred into neonatal
mice (Table II). Mice injected with antibodies to dsg1 reproduced
the clinical (Fig 5A), histologic (Fig 5B), and immunologic
(Fig 5C) features of PF and FS, i.e., subcorneal blisters and
antibodies bound to the ICS of lesional skin. Mice that received
af®nity-puri®ed antibodies to dsg3 developed clinical skin lesions
(Fig 5D) that showed suprabasilar acantholysis on histologic
examination (Fig 5E), and positive direct IF staining of the
epidermal ICS (Fig 5F). These clinical, histologic, and immuno-
logic features are identical to those seen in mice injected with anti-
dsg3 IgG from PV patients. The IgG fraction of all three sera (one
PF and two FS) when injected into neonatal mice induced clinical
disease (Fig 6A) and subcorneal acantholysis (Fig 6B) identical to
that found previously in other patients with PF.
DISCUSSION
In PV the presence of mucosal disease alone correlates with
antibodies to dsg3 (Miyagawa et al, 1999; Harman et al, 2000b).
Development of additional cutaneous disease has been correlated
with acquisition of antibodies to dsg1 (Miyagawa et al, 1999;
Harman et al, 2000b). An attractive hypothesis to explain these and
other ®ndings has been proposed (Udey and Stanley, 1999). In
mucosal epithelia, antibodies to dsg3 would cause disease due to
lack of compensation by dsg1. Antibodies to dsg3 alone would not
be able to mediate cutaneous disease because of ``compensation'' by
dsg1 in the skin. In a PV patient who acquires antibodies to dsg-1,
compensation by dsg1 is no longer possible, resulting in cutaneous
as well as mucosal disease. In PF by contrast, antibodies to dsg1
cannot cause mucosal disease as dsg3 is present at high levels
throughout the mucosa. They do cause cutaneous disease, how-
ever, which is limited to the upper epidermis where dsg3 is at very
low levels.
We detected antibodies to dsg3 in 19 of 276 patients with PF and
FS, in addition to the previously recognized antibodies to dsg1,
using highly sensitive and speci®c ELISA assays. We con®rmed our
results using immunoprecipitation. Using preincubation assays we
showed that reactivity with dsg3 was depleted by preincubation
with dsg3 but not dsg1. This suggests that there may be two
separate groups of antibodies in these patients, one group reactive
with dsg1 and one group reactive with dsg3. In addition we saw a
small drop in reactivity to dsg1 using preincubation with dsg3, and
a small drop in reactivity to dsg3 using preincubation with dsg1. As
there is a high degree of homology (see Fig 1) in the ectodomains
of dsg1 and dsg3, it is likely that a subpopulation of antibodies may
cross-react with both molecules. These results would need to be
developed using epitope mapping studies. Finally, we showed that
the antibodies to dsg3 from these patients are indeed pathogenic in
the mouse model, and reproduce the clinical, histologic, and
immunologic features of PV.
All 19 patients with PF and FS who had antibodies to dsg3 had
clinical and histologic features of PF, with no mucosal lesions. It is
possible that in these 19 patients with PF and FS, antibodies may
contribute to disease pathogenesis by blocking compensation by
dsg3 in the skin. As the total IgG fraction from three patients
produced only subcorneal acantholysis in the mouse model, the
levels of antibodies to dsg3 may be too low to cause mucosal disease
in these 19. Alternatively these patients may subsequently develop
mucosal disease as has been previously reported in nonendemic PF
Figure 6. The puri®ed total IgG fraction from PF and FS
patients with antibodies to both dsg1 and dsg3 produce clinical
and histologic features of PF in the mouse model. The total IgG
fraction from two patients with endemic PF and one with nonendemic
PF were puri®ed by ammonium sulfate precipitation and injected
intradermally into neonatal mice. All three sera reproduced the clinical
(A) and histologic features (B) of PF, namely super®cial blistering with
subcorneal acantholysis.
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in Japan (Ishii et al, 2000). Additional support for this suggestion
comes from the identi®cation of more clear-cut cases of an endemic
form of PV in the same regions of Brazil where FS is endemic.1
These authors collected a small group of young patients with a
severe mucocutaneous disease that on histologic and immunologic
grounds overlapped with PV. These patients need to be further
characterized in terms of antigenic targets.
In conclusion, these results show that the line between PF and
PV is becoming somewhat blurred, with the possibility of transition
between the two clinical forms existing, presumably by epitope
spreading (Lehman et al, 1992, 1993; Kaufman et al, 1993).
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